Full-Time

National Corporate Account Director

Posted on 11/19/2024

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$227k - $267.1kAnnually

Senior, Expert

Remote in USA

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Experience in oncology specialty distribution, specialty pharmacy, community oncology GPO, and community oncology key account management
  • Extensive customer relationships and experience
  • Experience launching oral oncology therapies in the community oncology setting with a focus on driving results and meeting or exceeding objectives
  • Demonstrated ability to meet assigned objectives and drive results within agreed upon timelines
  • Effective oral and written communication skills and ability to engage at all levels of the organization including C-Suite level relationships
  • Excellent negotiation skills with a focus on finding solutions to meet organizational goals
  • Collaborative work and communication style fostering cross-functional teamwork
  • Working knowledge of US healthcare policies and relevant legal, compliance, regulatory, and reporting requirements
  • Bachelor’s Degree; Master’s degree preferred
  • Strategic mindset and patient-centric approach to the business
  • Ability to thrive in a fast-paced, dynamic environment
  • 10+ years of pharmaceutical industry experience including current and/or previous oncology experience
  • 5+ years of related assigned account experience
  • Pharmaceutical field sales leadership experience preferred
Responsibilities
  • Execute the specialty distribution, community GPO, and key account strategies to ensure appropriate practice adoption and patient access
  • Negotiate specialty distribution (SDs) service agreements and related agreements, and maintain agreed upon service levels. Perform periodic business reviews
  • Negotiate service and data-sharing agreements with assigned oncology Specialty Pharmacy partners to meet brand objectives
  • Coordinate periodic business reviews
  • Identify and manage the execution of educational opportunities with assigned community oncology GPOs (ie Unity, Onmark, ION, etc.) to inform GPO members and support patient access through GPO meeting sponsorships opportunities and in-practice programs
  • Negotiate and manage GPO contracts to support patient access through in-practice dispensing
  • Manage relationships with community oncology key accounts with in-practice dispensing capabilities and centralized decision making
  • Collaborate with the field sales team to ensure coordination in key community oncology accounts
  • Support partnerships with assigned oncology trade organizations such as COA and NCODA
  • Analyze product volume, trends, and growth, for assigned accounts. Develop and implement account level business plans and work with market access marketing to develop segment strategies and resources
  • Monitor and ensure that partners adhere to contract terms

Corcept Therapeutics focuses on developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to improve understanding and care for cortisol-related conditions. The goal of Corcept is to advance the treatment of serious medical conditions linked to cortisol imbalance.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.

Help us improve and share your feedback! Did you find this helpful?